Oral Prodrug Of Astaxanthin, CDX-085, Achieves Significant Reduction Of Triglycerides, Atherosclerosis, And Cholesterol Levels In Animal Studies
Links shared publicly online about this topic.
- 291total visits
Oral Prodrug Of Astaxanthin, CDX-085, Achieves Significant Reduction Of Triglycerides, Atherosclerosis, And Cholesterol Levels In Animal Studies
Cardax Pharmaceuticals, Inc., a privately held pharmaceutical company headquartered in Honolulu, Hawaii, announced positive results presented at the Arteriosclerosis, Thrombosis and Vascular Biolo
View full resource at medicalnewstoday.com
Tags: Heart Disease, Circulatory Disorders, Atherosclerosis, Cholesterol, Pharma, Nature
Most Recently Shared on May 15, 2011 at 5:08 pm By:
Oral Prodrug Of Astaxanthin, #CDX-085- Reduction Of Triglycerides, Atherosclerosis, & #Cholesterol In Animal Studies http://bit.ly/kWygyz
Advertisement
